This paper is worth reading, specifically the last section on FTO's possible helpful role in treatment of AML, breast cancer and glioblastoma
https://cmb.i-learn.unito.it/pluginfile.php/17594/mod_resource/content/1/Chen_Du_2018.pdf
The paper is a review of all the known information and was written in mid 2018, so reasonably up to date.
sounds very promising for Bisantrene....and for RAC to draw on this known research when looking for investors, partners and big pharma interest.
This paper is worth reading, specifically the last section on...
-
- There are more pages in this discussion • 39 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.61 |
Change
-0.055(3.31%) |
Mkt cap ! $273.4M | |||
| Open | High | Low | Value | Volume |
| $1.66 | $1.68 | $1.61 | $271.5K | 166.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1996 | $1.61 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.68 | 1305 | 2 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |